Agenus to Host First 2026 Stakeholder Webcast

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its first Stakeholder Webcast of 2026, Access to Acceleration: Agenus’ Global Momentum Entering 2026 on Wednesday, January 28, 2026, at 4:00 p.m. ET.

The webcast will highlight how expanding global access pathways, strategic partnerships, and operational readiness are driving momentum for Agenus’ botensilimab and balstilimab (BOT+BAL) program entering 2026. The session will feature perspectives from Agenus leadership and a leading international oncology expert on progress across authorized access programs, clinical development, and priorities for the year ahead.

The session will be moderated by Garo Armen, PhD, Founder, Chairman, and Chief Executive Officer of Agenus, and will conclude with a live Q&A. Questions can be submitted in advance to [e-mail].

Featured Topics and Speakers

1. From Access to Acceleration: Strengthening the Global Foundation for BOT+BAL
Garo Armen, PhD
Founder, Chairman, and Chief Executive Officer, Agenus

• Dr. Armen will discuss the recently closed strategic collaboration with Zydus Lifesciences and how the transaction strengthens Agenus’ foundation for global development, authorized patient access programs, and commercial readiness for BOT+BAL. He will also outline priorities for 2026 as global interest in the program continues to grow.

2. Expanding Authorized Access: Clinical Perspective on BOT+BAL in Sarcoma
Robin Jones, MBBS, MRCP, BSc, MD
Consultant Medical Oncologist and Head of Sarcoma Unit, The Royal Marsden;
Professor of Medical Oncology, Institute of Cancer Research, London, UK

• Professor Jones will provide clinical perspective on the expansion of France’s Autorisation d’Accès Compassionnel (AAC) program to include patients with sarcoma, a population with significant unmet medical need following standard therapies. He will discuss how emerging clinical data and real-world experience are informing access decisions and expectations for immunotherapy in historically resistant tumor types.

3. Global Medical Affairs: Supporting Access and Readiness as Momentum Builds
José Iglesias, MD
Chief Medical Affairs Officer, Agenus

• Dr. Iglesias will discuss the expansion of Agenus’ global medical affairs organization and its role in supporting authorized access pathways, investigator engagement, and operational readiness as the BOT+BAL program advances through Phase 3 evaluation.

Stakeholder Briefing Details: